• Vivani Medical today reported positive top-line results from SLIM-1, a Phase 1 trial of its NPM-139 semaglutide implant versus Wegovy injections.
• No implant recipients experienced treatment-related adverse events, while gastrointestinal events occurred in the Wegovy group; weight loss was comparable between groups.
• The implant showed no rapid increases in drug exposure, supporting its tolerability profile.
• A Phase 2 dose-ranging weight-maintenance trial is expected to begin in 2027 for the implant, designed for once- or twice-yearly administration.
• Clinical development could expand to patients new to GLP-1 treatment based on the trial’s tolerability findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120800PRIMZONEFULLFEED9876106) on November 12, 2026, and is solely responsible for the information contained therein.